Trial Profile
Study of intravenous vernakalant compared with amiodarone in patients who had failed to attain sinus rhythm following failed electrical cardioversion (EVC) or who immediately returned to atrial fibrillation (IRAF) after briefly attaining sinus rhythm
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2015
Price :
$35
*
At a glance
- Drugs Vernakalant (Primary) ; Amiodarone
- Indications Atrial fibrillation
- Focus Therapeutic Use
- 23 Jun 2015 New trial record
- 12 Jun 2015 Results published in Eurospace, according to a Cardiome Pharma media release.
- 12 Jun 2015 Results published in a Cardiome Pharma media release.